Germany Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Germany Ankylosing Spondylitis Therapeutics Market is valued at around $0.21 Bn in 2022 and is projected to reach $0.26 Bn by 2030, exhibiting a CAGR of 2.8% during the forecast period 2023-2030.
Ankylosing spondylitis is an inflammatory condition that results in the vertebrae of the spine fusing together. This fusion reduces the flexibility of the spine and may lead to a hunched-over posture. According to the Spondylitis Association of America, Ankylosing spondylitis frequently manifests in young people between the ages of 17 and 45 if the ribs are involved (SAA). Ankylosing spondylitis is characterized by pain and stiffness that is greater in the morning or after lying down but becomes better with exercise. It could be challenging to breathe deeply. The lower back, hips, and buttocks can all experience discomfort and stiffness due to ankylosing spondylitis among others, night sweats, fatigue, and pain in ligaments and tendons.
Key elements fueling the market expansion include the increased incidences of Ankylosing spondylitis and arthritis, as well as strategic moves made by top industry participants. The illness frequently begins in early adulthood and is more prevalent in males than in women. The rising incidence of the condition and the rising demand for efficient therapies are driving the market for Ankylosing Spondylitis treatments to expand. The market is anticipated to grow even more as key players in the sector adopt efficient methods, giving a wealth of prospects for progress. The global market for ankylosing spondylitis is dominated by companies like Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many more. These businesses concentrate on research and development to introduce cutting-edge therapies to the market. They also engage in strategic alliances and acquisitions to increase their market share.
Market Drivers
Market Restraints
The clinical trial for Ankylosing Spondylitis (Bekhterev's disease), Sonelokimab, is now in phase I and is being conducted by Moonlake Immunotherapeutics. The phase transition success rate indication standard for moving phase I ankylosing spondylitis (Bekhterev's illness) medicines into phase II is 91%. For the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Ankylosing spondylitis, and hidradenitis suppurativa, sonelokimab (m-1095) is being developed. The drug candidate is injected under the skin.
Adult patients with active ankylosing spondylitis who have not improved with traditional therapy should consider RINVOQ. RINVOQ is a selective and reversible jak inhibitor that was discovered and created by Abbvie scientists. It is being researched for use in a number of immune-mediated inflammatory illnesses.
Key players
Novartis AbbVie Johnson & Johnson Pfizer UCB Celgene Corporation Amgen BMS Merck KGaA Eli Lilly and Company1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By End Users
By Drug Category
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.